
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics Inc. is positioned favorably in the biotechnology sector, focusing on its proprietary TANGO approach to develop antisense oligonucleotides, particularly zorevunersen, which shows promising results for treating Dravet syndrome. The company's updated revenue projections for zorevunersen suggest enhanced earnings potential, with expectations for a FY28 launch and a target increase to $32, with possibilities for further upside should the FDA expedite the approval process. Furthermore, the strong efficacy data from clinical trials, indicating an approximately 82% seizure reduction and notable cognitive improvements, significantly bolsters confidence in the company’s pipeline and reduces risks associated with the upcoming Phase 3 EMPEROR study.
Bears say
Stoke Therapeutics Inc has experienced a significant 15% pullback in share value, which the analyst considers a misplaced reaction tied to the unrelated FDA filing strategy announcement by QURE. The company is grappling with bleak natural history outcomes for Dravet syndrome, where existing therapies have limited effectiveness, evidenced by declining or plateauing Vineland scores, which may hinder zorevunersen's adoption if it fails to offer substantial long-term benefits. Additionally, there is a substantial risk associated with potential commercial execution failures or the inability to meet market expectations, which could adversely affect the company's stock performance.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares